Literature DB >> 36268123

Small-Molecule Ebselen Binds to YTHDF Proteins Interfering with the Recognition of N 6-Methyladenosine-Modified RNAs.

Mariachiara Micaelli1, Andrea Dalle Vedove1, Linda Cerofolini2,3, Jacopo Vigna4, Denise Sighel1, Sara Zaccara5, Isabelle Bonomo1, Georgios Poulentzas1, Emanuele Filiberto Rosatti1, Giulia Cazzanelli1, Laura Alunno1, Romina Belli6, Daniele Peroni6, Erik Dassi1, Shino Murakami5, Samie R Jaffrey5, Marco Fragai2,3, Ines Mancini4, Graziano Lolli1, Alessandro Quattrone1, Alessandro Provenzani1.   

Abstract

YTHDF proteins bind the N 6-methyladenosine (m6A)-modified mRNAs, influencing their processing, stability, and translation. Therefore, the members of this protein family play crucial roles in gene regulation and several physiological and pathophysiological conditions. YTHDF proteins contain a hydrophobic pocket that accommodates the m6A embedded in the RRACH consensus sequence on mRNAs. We exploited the presence of this cage to set up an m6A-competitive assay and performed a high-throughput screen aimed at identifying ligands binding in the m6A pocket. We report the organoselenium compound ebselen as the first-in-class inhibitor of the YTHDF m6A-binding domain. Ebselen, whose interaction with YTHDF proteins was validated via orthogonal assays, cannot discriminate between the binding domains of the three YTHDF paralogs but can disrupt the interaction of the YTHDF m6A domain with the m6A-decorated mRNA targets. X-ray, mass spectrometry, and NMR studies indicate that in YTHDF1 ebselen binds close to the m6A cage, covalently to the Cys412 cysteine, or interacts reversibly depending on the reducing environment. We also showed that ebselen engages YTHDF proteins within cells, interfering with their mRNA binding. Finally, we produced a series of ebselen structural analogs that can interact with the YTHDF m6A domain, proving that ebselen expansion is amenable for developing new inhibitors. Our work demonstrates the feasibility of drugging the YTH domain in YTHDF proteins and opens new avenues for the development of disruptors of m6A recognition.
© 2022 The Authors. Published by American Chemical Society.

Entities:  

Year:  2022        PMID: 36268123      PMCID: PMC9578143          DOI: 10.1021/acsptsci.2c00008

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  67 in total

1.  A Reader-Based Assay for m6A Writers and Erasers.

Authors:  Lars Wiedmer; Stefanie Alexandra Eberle; Rajiv Kumar Bedi; Paweł Śledź; Amedeo Caflisch
Journal:  Anal Chem       Date:  2019-02-04       Impact factor: 6.986

2.  Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives.

Authors:  Christopher M Goins; Steven Dajnowicz; Sandeep Thanna; Steven J Sucheck; Jerry M Parks; Donald R Ronning
Journal:  ACS Infect Dis       Date:  2017-03-21       Impact factor: 5.084

3.  A novel biologically active seleno-organic compound--II. Activity of PZ 51 in relation to glutathione peroxidase.

Authors:  A Wendel; M Fausel; H Safayhi; G Tiegs; R Otter
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

4.  Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain.

Authors:  Graziano Lolli; Roberto Battistutta
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-09-20

5.  Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.

Authors:  Jasmin Paris; Marcos Morgan; Joana Campos; Gary J Spencer; Alena Shmakova; Ivayla Ivanova; Christopher Mapperley; Hannah Lawson; David A Wotherspoon; Catarina Sepulveda; Milica Vukovic; Lewis Allen; Annika Sarapuu; Andrea Tavosanis; Amelie V Guitart; Arnaud Villacreces; Christian Much; Junho Choe; Ali Azar; Louie N van de Lagemaat; Douglas Vernimmen; Ali Nehme; Frederic Mazurier; Tim C P Somervaille; Richard I Gregory; Dónal O'Carroll; Kamil R Kranc
Journal:  Cell Stem Cell       Date:  2019-04-25       Impact factor: 24.633

Review 6.  Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers.

Authors:  Xin-Yuan Dai; Liang Shi; Zhi Li; Hai-Yan Yang; Ji-Fu Wei; Qiang Ding
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

Review 7.  Development of ebselen for the treatment of sensorineural hearing loss and tinnitus.

Authors:  Jonathan Kil; E Emily Harruff; Ryan J Longenecker
Journal:  Hear Res       Date:  2021-02-19       Impact factor: 3.208

Review 8.  N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function.

Authors:  Yamei Niu; Xu Zhao; Yong-Sheng Wu; Ming-Ming Li; Xiu-Jie Wang; Yun-Gui Yang
Journal:  Genomics Proteomics Bioinformatics       Date:  2012-12-21       Impact factor: 7.691

9.  The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.

Authors:  Megan Garland; Andrew J Hryckowian; Martina Tholen; Kristina Oresic Bender; William W Van Treuren; Sebastian Loscher; Justin L Sonnenburg; Matthew Bogyo
Journal:  Cell Rep Med       Date:  2020-04-21

10.  METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes.

Authors:  Elena V Moroz-Omori; Danzhi Huang; Rajiv Kumar Bedi; Sherry J Cheriyamkunnel; Elena Bochenkova; Aymeric Dolbois; Maciej D Rzeczkowski; Yaozong Li; Lars Wiedmer; Amedeo Caflisch
Journal:  ChemMedChem       Date:  2021-07-29       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.